Despite headwinds, Vertex Pharmaceuticals Inc.'s Orkambi won favor from members of the FDA's Pulmonary-Allergy Drugs Advisory Committee (PADAC), who voted 12-1 to recommend approval despite plenty of questions about the prospective new therapy that combines the firm's already approved Kalydeco (ivacaftor) and lumacaftor for homozygous F508del cystic fibrosis (CF) patients.